- Theralase (TLT) has demonstrated proof-of-concept for its Canadian-made COVID-19 vaccine
- It has shown that its light-activated TLD-1433 compound was effective in deactivating SARS-CoV-2 by up to 99.99 per cent compared to the control in an in-vitro study
- The result has laid the groundwork for evaluating if the vaccine prevents animals from contracting COVID-19
- Theralase is a clinical-stage pharmaceutical company dedicated to the research and development of light-activated photo dynamic compounds
- Theralase (TLT) is up by 17.72 per cent trading at $0.465 per share
Theralase (TLT) has demonstrated proof-of-concept for its Canadian-made COVID-19 vaccine.
In collaboration with the University of Manitoba (UM), the company demonstrated that its photodynamic compound (PDC), TLD-1433, was effective in the rapid destruction of various viruses, including H1N1 Influenza, Zika and a Biological Safety Level-2 coronavirus.
Further research with UM also identified that the spike protein responsible for coronavirus transmission into a host cell remained intact after light-activated TLD-1433 inactivation, suggesting that the PDC could potentially stimulate an antibody immune response in a mammalian host.
The company and the Public Health Agency of Canada’s National Microbiology Laboratory are currently collaborating on a COVID-19 vaccine by inactivating the SARS-CoV-2 virus with light-activated TLD-1433.
The partners are reporting today that the light-activated compound was effective in inactivating SARS-CoV-2 by up to 99.99 per cent compared to the control in an in-vitro study.
The result has laid the groundwork for evaluating if the vaccine prevents animals from contracting COVID-19.
“Based on this encouraging data,” stated Arkady Mandel, Theralase’s Interim CEO, “the company intends to move forward in the research, development and commercialization of the Theralase COVID-19 vaccine.”
Theralase is a clinical-stage pharmaceutical company dedicated to the research and development of light-activated photodynamic compounds.
Theralase (TLT) is up by 17.72 per cent trading at $0.465 per share as of 11:22 am EST.
